Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05325528
Status:
RECRUITING
Last Update Posted:
2023-02-01
First Post:
2022-03-21
Brief Title:
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
An Exploratory Study of Tislelizumab in Combination With Oxaliplatin and Tegafur for the Treatment of Gastric Cancer With Liver Metastases
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Liver metastases are one of the most common sites of metastasis in advanced gastric cancer Chemotherapy remains the mainstay of treatment for these patients but combination chemotherapy has encountered a bottleneck in improving patient survival with no significant improvement in survival rates at 1 3 or 5 years In a previous phase II clinical study we not only observed the survival benefits of Tislelizumab in the treatment of GI tumors such as liver oesophageal and some gastric cancers but also confirmed the safety of Tislelizumab in the treatment of advanced GI tumors This study is a clinical study of PD-1 monoclonal antibody Tislelizumab in combination with SOX Tegafur Oxaliplatin for the treatment of liver metastases from gastric cancer It aims to further explore a new combination therapy for liver metastases from gastric cancer which is safe and effective for patients with difficult-to-treat disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None